Bespak signs new scale-up and commercial supply agreement

Published: 14-Sep-2016
Drug Delivery Medical Devices Pharmaceutical

Pressurised metered dose inhaler technology will be used in respiratory devices to treat COPD


Bespak, part of Consort Medical, and AstraZeneca have signed a multi-year scale-up and commercial supply agreement for Bespak's proprietary pressurised metered dose inhaler (pMDI) valve and actuator technology.

These components will be assembled with AstraZeneca’s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

AstraZeneca announced that its device was approved by the US Food and Drug Administration on 25 April 2016.

These products will be manufactured in Bespak’s existing King’s Lynn facility. Going forwards the project will be referred to as VAL100.

'We are delighted to have successfully concluded this agreement with AstraZeneca,' said Jon Glenn, Chief Executive Officer of Consort Medical. 'This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.'

  • Companies:
  • Bespak
  • AstraZeneca
  • Consort Medical plc
See more

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

Read more
The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously

Trending Articles

  1. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  2. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  3. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  4. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  5. Adragos Pharma enhances its sterile injectable production capabilities with new €13m ampoule filling line The novel line at the CDMO's Livron-sur-Drôme site in France will allow the company to manufacture more than 160 million ampoules for sterile injectables annually

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Sustainability

Bespak and Orbia Fluor & Energy Materials partner to create climate-friendly inhalers

The two companies will create pMDIs with an optimised sustainability profile with Orbia's low global warming potential (GWP) propellant, Zephex 152a
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Drug Delivery

Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle

AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Regulatory

AstraZeneca’s Tagrisso plus chemo for EGFR-mutated lung cancer approved in Japan

The approval comes off the back of the positive Phase III FLAURA2 trial results, showing a significant improvement in PFS compared with Tagrisso monotherapy
Subscribe now